TRx0237 is a small molecule that inhibits Tau aggregation; it is being applied to patients with mild Alzheimer’s disease, and the results of this treatment are still being awaited [42] from clinical trial NCT03446001 [43]. Here, MAPT is linked to Alzheimer disease.